Intrarectal instillation of clostridium difficile toxin a triggers colonic inflammation and tissue damage: Development of a novel and efficient mouse model of clostridium difficile toxin exposure

Infection and Immunity

Volumn 80, Issue 12, 2012, Pages 4474-4484

  Hirota, Simon A ^a   Iablokov, Vadim ^b   Tulk, Sarah E ^a   Schenck, L Patrick ^a   Becker, Helen ^a   Nguyen, Jimmie ^a   Bashir, Samir Al ^a   Dingle, Tanis C ^b   Laing, Austin ^b   Liu, Jianrui ^b   Li, Yan ^a   Bolstad, Jeff ^b   Mulvey, George L ^b   Armstrong, Glen D ^b   Macnaughton, Wallace K ^b   Muruve, Daniel A ^a   Macdonald, Justin A ^a   Beck, Paul L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOPEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CELL DEATH; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLON INJURY; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; FEMALE; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; MACROPHAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE INJURY;

ADMINISTRATION, RECTAL; ANIMALS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; COLON; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; FEMALE; HUMANS; INFLAMMATION; MICE; MICE, INBRED C57BL;

EID: 84870832929     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00933-12     Document Type: Article

References (50)

1. Abrams GD, Allo M, Rifkin GD, Fekety R, Silva J, Jr. 1980. Mucosal damage mediated by clostridial toxin in experimental clindamycinassociated colitis. Gut 21:493-499.
2. Alcantara C, Stenson WF, Steiner TS, Guerrant RL. 2001. Role of inducible cyclooxygenase and prostaglandins in Clostridium difficile toxin A-induced secretion and inflammation in an animal model. J. Infect. Dis. 184:648-652.
3. Boey CC, Ramanujam TM, Looi LM. 1997. Clostridium difficile-related necrotizing pseudomembranous enteritis in association with Henoch- Schonlein purpura. J. Pediatr. Gastroenterol. Nutr. 24:426-429.
4. Burakoff R, et al. 1995. Effects of purified Clostridium difficile toxin A on rabbit distal colon. Gastroenterology 109:348-354.
5. Butterton JR, Ryan ET, Acheson DW, Calderwood SB. 1997. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains. Infect. Immun. 65: 2127-2135.
6. Carneiro BA, et al. 2006. Caspase and bid involvement in Clostridium difficile toxin A-induced apoptosis and modulation of toxin A effects by glutamine and alanyl-glutamine in vivo and in vitro. Infect. Immun. 74: 81-87.
7. Carter GP, Rood JI, Lyras D. 2010. The role of toxin A and toxin B in Clostridium difficile-associated disease: past and present perspectives. Gut Microbes 1:58-64.
8. Castagliuolo I, et al. 2001. Endogenous corticosteroids modulate Clostridium difficile toxin A-induced enteritis in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 280:G539-G545.
9. Castagliuolo I, et al. 1998. Clostridium difficile toxin A stimulates macrophage- inflammatory protein-2 production in rat intestinal epithelial cells. J. Immunol. 160:6039-6045.
10. Chae S, et al. 2006. Epithelial cell I kappa B-kinase beta has an important protective role in Clostridium difficile toxin A-induced mucosal injury. J. Immunol. 177:1214-1220.
11. Chen X, et al. 2008. A mouse model of Clostridium difficile-associated disease. Gastroenterology 135:1984-1992.
12. Couzigou P, et al. 1982. Necrotizing enterocolitis during agranulocytosis and Clostridium difficile colitis. Lancet ii:720.
13. de Araujo Junqueira AF, et al. 2011. Adenosine deaminase inhibition prevents Clostridium difficile toxin A-induced enteritis in mice. Infect. Immun. 79:653-662.
14. Dignan CR, Greenson JK. 1997. Can ischemic colitis be differentiated from C. difficile colitis in biopsy specimens? Am. J. Surg. Pathol. 21:706-710.
15. Gerding DN, Brazier JS. 1993. Optimal methods for identifying Clostridium difficile infections. Clin. Infect. Dis. 16(Suppl. 4):S439-S442.
16. Gerhard R, et al. 2008. Glucosylation of Rho GTPases by Clostridium difficile toxin A triggers apoptosis in intestinal epithelial cells. J. Med. Microbiol. 57:765-770.
17. Hecht G, Koutsouris A, Pothoulakis C, LaMont JT, Madara JL. 1992. Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology 102:416-423.
18. Hecht G, Pothoulakis C, LaMont JT, Madara JL. 1988. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J. Clin. Invest. 82:1516-1524.
19. Hirota SA, et al. 2010. Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury. Gastroenterology 139:259-269.
20. Hirota SA, et al. 2011. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm. Bowel Dis. 17:1359-1372.
21. Hodges K, Gill R. 2010. Infectious diarrhea: cellular and molecular mechanisms. Gut Microbes 1:4-21.
22. Hull MW, Beck PL. 2004. Clostridium difficile-associated colitis. Can. Fam. Phys. 50:1536-1540.
23. Ishida Y, et al. 2004. Essential involvement of IFN-gamma in Clostridium difficile toxin A-induced enteritis. J. Immunol. 172:3018-3025.
24. Kelly CP, et al. 1994. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J. Clin. Invest. 93:1257-1265.
25. Kim H, Rhee SH, Pothoulakis C, Lamont JT. 2007. Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 upregulation of Fas ligand. Gastroenterology 133:875-886.
26. Kuijper EJ, van Dissel JT, Wilcox MH. 2007. Clostridium difficile: changing epidemiology and new treatment options. Curr. Opin. Infect. Dis. 20:376-383.
27. Linevsky JK, et al. 1997. IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am. J. Physiol. 273: G1333-G1340.
28. Lyerly DM, Saum KE, Macdonald DK, Wilkins TD. 1985. Effects of Clostridium difficile toxins given intragastrically to animals. Infect. Immun. 47:349-352.
29. Lyras D, et al. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179.
30. Mahida YR, et al. 1998. Effect of Clostridium difficile toxin A on human colonic lamina propria cells: early loss of macrophages followed by T-cell apoptosis. Infect. Immun. 66:5462-5469.
31. Mahida YR, Makh S, Hyde S, Gray T, Borriello SP. 1996. Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. Gut 38: 337-347.
32. Mathew OP, Bhatia JS, Richardson CJ. 1984. An outbreak of Clostridium difficile necrotizing enterocolitis. Pediatrics 73:265-266.
33. McFarland LV, Beneda HW, Clarridge JE, Raugi GJ. 2007. Implications of the changing face of Clostridium difficile disease for health care practitioners. Am. J. Infect. Control 35:237-253.
34. Morris GP, et al. 1989. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795-803.
35. Ng EK, et al. 2003. Human intestinal epithelial and smooth muscle cells are potent producers of IL-6. Mediators Inflamm. 12:3-8.
36. Ng J, et al. 2010. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 139:542-552.
37. O'connor JR, Johnson S, Gerding DN. 2009. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136: 1913-1924.
38. Pothoulakis C, et al. 1998. Substance P receptor expression in intestinal epithelium in Clostridium difficile toxin A enteritis in rats. Am. J. Physiol. 275:G68-G75.
39. Riegler M, et al. 1995. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J. Clin. Invest. 95:2004-2011.
40. Ryan ET, et al. 1997. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect. Immun. 65:2941-2949.
41. Savidge TC, et al. 2003. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 125:413-420.
42. Solomon K, Webb J, Ali N, Robins RA, Mahida YR. 2005. Monocytes are highly sensitive to Clostridium difficile toxin A-induced apoptotic and nonapoptotic cell death. Infect. Immun. 73:1625-1634.
43. Steiner TS, Flores CA, Pizarro TT, Guerrant RL. 1997. Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin. Diagn. Lab. Immunol. 4:719-722.
44. Taylor NS, Bartlett JG. 1979. Partial purification and characterization of a cytotoxin from Clostridium difficile. Rev. Infect. Dis. 1:379-385.
45. Triadafilopoulos G, Pothoulakis C, O'brien MJ, LaMont JT. 1987. Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology 93:273-279.
46. Triadafilopoulos G, Pothoulakis C, Weiss R, Giampaolo C, Lamont JT. 1989. Comparative study of Clostridium difficile toxin A and cholera toxin in rabbit ileum. Gastroenterology 97:1186-1192.
47. Viswanathan VK, Mallozzi MJ, Vedantam G. 2010. Clostridium difficile infection: an overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes 1:234-242.
48. Vohra P, Poxton IR. 2012. Induction of cytokines in a macrophage cell line by proteins of Clostridium difficile. FEMS Immunol. Med. Microbiol. 65:96-104.
49. Warny M, et al. 2000. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J. Clin. Invest. 105:1147-1156.
50. Wren B, Heard SR, Tabaqchali S. 1987. Association between production of toxins A and B and types of Clostridium difficile. J. Clin. Pathol. 40: 1397-1401.